SABR Update Breast SSG June 2017.

Slides:



Advertisements
Similar presentations
Pulmonary Stereotactic Ablative Radiotherapy:
Advertisements

Oncologic Drugs Advisory Committee
An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.
ASCO G.U Lawrence H. Einhorn.
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Living Beyond Breast Cancer Liver and Lung Metastases Workshop April 29, 2012 Paul B. Gilman, MDLankenau Medical Center.
Resection For Lung Metastases M62 Coloproctology Course.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer
Evidence Based Approach 5-Year Survival Rate for Breast Cancer Stage IV is 14% 2 to 5 percent become long-term survivors, possibly cured of their disease.
NMDT (%)Path (%)NOS (%)CNS (%) Weston Area Health  70.5  5.7  66.3  Yeovil District Hospital  54.9  22.9  82.9  University Hospitals.
Hysterectomy after Chemoradiotherapy for Stage Ib2 and IIb Cervical Cancer Vivek Nama UHBT.
First line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer – a Cochrane Collaboration.
Mesothelioma in the South West Gerry Slade Mesothelioma UK CNS.
Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.
1SOLO 2 - June
Charlie Comins 10/11/15. Bristol Experience Treated first patient in Feb 2014 Aim to treat 12 patients in first year Treated 25 patients in first 12 months.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage.
SCTS Education day “Radiotherapy in 2016”
ELIGIBILITY CRITERIA- Summarised
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Brain imaging prior to lung cancer resection
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Javelin A Phase III, open-label, multicenter trial of avelumab (MSB C) versus platinum-based doublet as a first-line treatment of recurrent or.
Shyam B. Paryani M.D., M.S., M.H.A & Nitesh N. Paryani, M.D.
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Updates in Prostate Cancer Prepared for GP master class – Sept 2016
Bladder Cancer and Prostatic Cancer
ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
Breast SSG: SABR and Oligometastatic Disease
Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
CUP SSG May 2016 Dr Matt sephton
Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment CCO Independent Conference Coverage* of the 2016.
Colorectal SSG: SABR and Oligometastatic Disease
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Acquired EGFR TKI resistance: What are the current therapeutic strategies? Gregory J. Riely.
until tumour progression until tumour progression
Dr T P E Wells 13 July 2018 Breast SSG Bath
New developments in oncological treatment for Stage 3 NSCLC
Jonathan W. Friedberg M.D., M.M.Sc.
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Baselga J et al. SABCS 2009;Abstract 45.
All for One: Multidisciplinary Management in EGFR-Mutated NSCLC
What’s new in stage III lung cancer?
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases  Tao.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Role for XRT in treatment of early stage Follicular lymphoma?
Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program
CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy (SBRT)) in Extracranial oligometastases (CRUK/14/038)
General strategies of Cancer Treatment and evaluation of Response
Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.
Updates in Best Practices in Non-Small Cell Lung Cancer
Uncovering the Right Sequence
Presentation transcript:

SABR Update Breast SSG June 2017

SABR in Bristol First patient treated in February 2014 In past 3 years: 330 referrals 250 patients treated Includes patients treated with oligometastatic disease through CtE Areas treated include: lung, liver, adrenal, lymph node and bone

Referral Centers PLYMOUTH EXETER TORBAY BARNSTABLE TAUNTON YEOVIL BATH UHB NBT GLOUCESTER CHELTENHAM WESTON

OVERALL SURVIVAL OVERALL SURVIVAL AT 1 YEAR WAS 87% (95% CI 80 – 94%) AND 2 YEARS 78.8% (95% CI 66.8 – 90.8%). THIS IS COMPARABLE WITH PUBLISHED DATA PFS AND LRR WILL BE GENERATED ONCE WE HAVE FURTHER DATA FROM LOCAL CENTRES AND CENTRAL RADIOLOGY REVIEW

Case History: CT before and 12 months after treatment

But in reality……

Things are not quite so simple……

Indications for SABR Medically-inoperable lung cancer Good evidence base; standard of care Oligo-metastatic disease Synchronous Metachronous Oligo-progressive disease Progression in a small number of sites while patient on maintenance treatment Stage IV disease Combining SABR with systemic treatment - immunotherapy

Oligometastatic Disease: Randomised trials SARON trial synchronous metastatic disease in NSCLC Sequential chemoRT followed SABR to up to 3 metastatic sites vs palliative chemo CORE trial metachronous disease in lung, breast and prostate SABR to up to 3 metastatic sites vs standard of care Must have minimum of 6 months disease free interval HALT trial oligoprogressive disease in patients with driver mutation SABR and continued TKI vs change in systemic treatment

CORE trial schema Randomise (1:1) SBRT + Standard of Care NSCLC, breast or prostate cancer patients Completed radical treatment ≤3 extra cranial metachronous oligometastases Suitable for SBRT Randomise (1:1) Standard of Care SBRT + Standard of Care Standard of Care defined prior to randomisation May include further chemotherapy, hormone therapy, palliative radiotherapy or observation at PI discretion

Aims/Objectives Primary Secondary To evaluate if the addition of SBRT to SoC improves PFS Secondary

Secondary Aims/Objectives To demonstrate feasibility of recruitment To demonstrate deliverability of SBRT within dosimetric constraints To evaluate if the addition of SBRT to SoC improves OS To evaluate the acute and late toxicity associated with the addition of SBRT to SoC To evaluate the lesion local control rates in those receiving SBRT To compare the quality of life (QoL) in patients receiving SBRT compared to those receiving SoC alone To investigate and evaluate resource use and costs of SBRT and SoC therapy within the trial setting.